Novonix’s Plan to Reignite Investor Confidence Beyond the Stellantis Setback

Refocusing After a Major Partnership Shock

Novonix (ASX: NVX), like many critical mineral names, has faced a steep sell-off in recent months, sliding from around A$1.00 in October to roughly A$0.44 today. The sharp decline was largely triggered by the loss of a major supply agreement with Stellantis, which had been set to deliver 86,000 tonnes of battery material, a significant setback for the company’s near-term growth narrative. However, beyond the immediate hit, today’s investor presentation provided a clearer view of how management plans to reset expectations and refocus on the long-term opportunity in high-performance anode materials.

While confidence has understandably taken a knock, the underlying story remains intact for investors who believe in the structural tailwinds of energy storage and electrification. Novonix’s strategy now leans toward proving commercial scalability, deepening US partnerships, and maintaining its cost advantage as domestic demand for synthetic graphite accelerates.

What are the Best Critical Minerals ASX Stocks to invest in right now?

Check our buy/sell tips

Novonix Taps Into the Graphite Supercycle as the US Pushes for Supply Independence

The foundation of a long-term growth story lies in powerful macro tailwinds reshaping the global graphite market. China currently accounts for roughly 95% of global graphite supply, and recurring export restrictions have amplified concerns about supply chain security. The US response, introducing tariffs on Chinese graphite, has already pushed domestic prices up to around US$14 per kilogram, effectively creating a pricing umbrella that benefits emerging non-Chinese producers.

The company is positioning itself to capitalise on growing demand for high-performance synthetic graphite, which remains the preferred choice for reliability and energy density in advanced battery applications. However, it is worth noting that Novonix’s production facilities still require time before reaching large-scale commercial output. In its latest presentation, management reiterated its ambition to expand production capacity tenfold by 2035, underscoring its confidence in the long-term potential of its US-based anode materials business.

Novonix Secures Funding to Power Next-Phase Growth

NVX still holds long-term supply agreements with Panasonic Energy and POSCO, totalling 42,000 tonnes once qualification is complete. Management also stated that they are in commercial discussions with around 15 potential OEM and cell manufacturing customers currently in various qualification phases. This indicates that potential customer demand is beginning to build, which could translate into meaningful revenue opportunities once formal agreements are secured.

However, it is important to recognise that Novonix’s synthetic graphite process is highly capital-intensive. Scaling production to meet demand expectations requires substantial external funding. This has already been reflected in the company’s recent financing moves, including a US$100 million convertible debt facility and a conditional commitment for a US$754 million loan from the US Department of Energy. While these funding channels provide critical support for growth, they also highlight the company’s reliance on external capital to achieve commercial scale and long-term profitability.

The Invetsors Takeaway For NVX

The company’s future outlook centres on ramping up production at its Riverside facility to reach full 20,000 tonnes per annum (Tpa) capacity by late 2026. Management also plans to secure new Tier 1 OEM supply agreements beyond Panasonic and POSCO while targeting positive operating cash flow by 2027.

From an investment perspective, Novonix looks increasingly interesting after a near 60% share price decline. Following such a heavy drawdown, this could be a constructive time for investors to revisit the stock’s fundamentals and long-term potential. For the next leg higher, the market will want to see tangible progress, particularly in converting OEM discussions into binding partnerships and demonstrating successful scale-up execution.

The planned ramp-up from pilot scale to 20,000 Tpa at Riverside and eventually to 50,000 Tpa at Enterprise South will be critical. However, these transitions often come with technical and process challenges that can delay output or inflate costs. The recent termination of the Stellantis partnership is a reminder that commercial execution risk remains high. Still, if Novonix can deliver on its capacity targets and lock in new Tier 1 customers, the upside from these levels could be meaningful for long-term investors willing to ride out the volatility.